Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07722611

PHASE2/PHASE3

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone. Researchers want to learn if a trial medicine called bomedemstat, also called MK-3543, can treat PV. In this study, researchers will compare bomedemstat to 2 usual treatments for PV. The goal of this study is to learn if more participants who take bomedemstat reach healthy blood cell counts and avoid major health problems from PV, compared to those who receive a usual treatment.

Official title: A Phase 2/3, Randomized, Open-label, Active-comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) Versus Best Available Therapy in Participants With Polycythemia Vera Who Have an Inadequate Response to or Are Intolerant to Hydroxyurea

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

380

Start Date

2026-09-21

Completion Date

2032-11-30

Last Updated

2026-07-23

Healthy Volunteers

Conditions

Polycythemia Vera

Interventions

DRUG

Bomedemstat

Oral Capsule

DRUG

Ruxolitinib

Oral Tablet

DRUG

Ropeginterferon alfa-2b

Subcutaneous Solution

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has confirmed local diagnosis of polycythemia vera (PV) per World Health Organization (WHO) diagnostic criteria for PV * Must have discontinued prior cytoreductive therapy for condition under study for protocol specified duration * Has failed at least one prior line of cytoreductive therapy to lower hematocrit * Has a history of inadequate response, resistance to, or intolerant to hydroxyurea (HU) per protocol specified criteria * Has no evidence of splenomegaly and no symptoms attributable to splenomegaly, including early satiety, left upper quadrant discomfort, or splenic pain * Has locally assessed bone marrow (BM) fibrosis score of Grade 0 or Grade 1 as per modified version of the European Consensus Criteria for Grading Myelofibrosis * Human Immunodeficiency Virus (HIV)-infected participants have well controlled HIV on antiretroviral therapy (ART) * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load * Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable * Participants must be able to swallow oral medication and follow instructions for at home dosing of bomedemstat Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has history of any illness/impairment of gastrointestinal (GI) function that might interfere with drug absorption * Has evidence at the time of screening of increased risk of bleeding * Has history of malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Is currently receiving anticancer therapy * Has an active infection requiring systemic therapy * Has had major surgical procedure ≤4 weeks before first dose of study intervention or has not recovered from side effects of major surgical procedure

Clinical Research Directory

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

Summary

Key Details

Conditions

Interventions

Eligibility Criteria